The integration of immune checkpoint inhibitors into first-line treatment has markedly improved outcomes for extensive-stage small cell lung cancer (ES-SCLC). Adebrelimab, a PD-L1 inhibitor, demonstrated superior overall survival in the phase 3 CAPSTONE-1 trial. We present a detailed case of a 62-year-old male with ES-SCLC who achieved a progression-free survival (PFS) of 33 months following a multimodal regimen of adebrelimab plus chemotherapy, consolidative thoracic radiotherapy, and maintenance immunotherapy. Despite low PD-L1 expression (TPS<1%), the patient exhibited profound and durable tumor regression, with the primary mass shrinking from 146×158×217 mm to 51×21 mm. Treatment was well-tolerated with only grade 1–2 adverse events. This report underscores the potential for long-term disease control with adebrelimab-based therapy even in biomarker-unselected populations and highlights the importance of combined modality strategies.
Lung cancer is the third most common malignancy in the United States and remains the leading cause of cancer-related mortality worldwide. Despite ongoing advances in diagnosis and therapy, survival rates for patients with lung cancer remain unsatisfactory (1). In recent years, in…
Purpose To describe real-world treatment patterns and outcomes among patients with extensive-stage small cell lung cancer (ES-SCLC) treated with first-line chemotherapy plus durvalumab as in CASPIAN trial within Expanded Access Program, with a focus on the use and impact of conso…
Esophageal squamous cell carcinoma (ESCC) is a highly lethal malignant tumor. Immune checkpoint inhibitors (ICIs), represented by sintilimab, have become an important treatment option for advanced ESCC, but they may induce immune-related adverse events (irAEs) involving multiple…
Esophageal squamous cell carcinoma(ESCC) carries a poor prognosis with low survival rates, frequently due to advanced disease at diagnosis. Colonic metastasis from ESCC is exceptionally rare. This report describes the case of a 68-year-old male with locally advanced ESCC who deve…
Background Adenomatoid tumor is a rare benign neoplasm of mesothelial origin, most commonly arising in the epididymis, vas deferens, and tunica vaginalis; primary occurrence in the testis is extremely rare. Cryptorchidism is recognized as a risk factor for testicular germ cell tu…
Introduction Neuroendocrine prostate cancer (NEPC) is an aggressive treatment-associated lineage state emerging with potent androgen receptor (AR) pathway inhibition. Although treatment-emergent NEPC is increasingly recognized, the transcriptional consequences of sustained AR sup…